NCT06100237 - Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Teclistamab

Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.

DRUG

Talquetamab

Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.

DRUG

Daratumumab SC

Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Carl Ola Landgren, MD, PhD

OTHER